Briefing

Industry news

Industry briefing

NEWS

Biocon Biologics acquires biosimilars business of Viatris for $3bn

Biocon subsidiary Biocon Biologics has acquired the international biosimilars business of Viatris in a deal totalling $3bn

news

Blacksmith Medicines to merge with Forge Therapeutics

Blacksmith Medicines has signed a definitive merger agreement with Forge Therapeutics to create a combined entity to develop metalloenzyme-targeted drugs

Briefing

Element announces $200 Genome on benchtop sequencing system

Element Biosciences announced that a new throughput-based option for its AVITI System will provide sequencing on a benchtop for $200 a genome

Industry news

Industry briefing

01/19/2023 09:33:23
  • Home | CRISPR gene therapies cut through in 2023
  • In this issue
  • Contents
  • Mimotopes Company Insight
  • Tripletree
  • Briefing
  • Industry news
  • The pharma industry briefing
  • HOF Sonderanlagenbau
  • Owen Mumford Company Insight
  • Owen Mumford Aidaptus
  • Comment
  • High hopes for mRNA anti-cancer vaccines with early successes
  • Cell therapies might revolutionise treatment for multiple sclerosis patients
  • Downturn for top biopharma companies as Covid-19 vaccine demand falls in Q3
  • Inflation threatens supply of life-saving generics to Europe
  • Data is the key to a safer and more controlled pharmaceutical cold-chain
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • In Depth
  • CRISPR gene therapies: Is 2023 a milestone year in the making?
  • Tracking the ups and downs of pharma deals
  • Regulation starts to catch up with AI in pharma
  • Next on trial diversity: Embracing participants with cognitive impairment
  • Digital twins: The next frontier to ease clinical trial conduct
  • CMO Moves: Regulatory catalysts for therapy manufacturing -January
  • Events
  • Next issue